Peer-influenced content. Sources you trust. No registration required. This is HCN.
Cancer Therapy Advisor
Discover how SABR is setting a new standard in the treatment of inoperable renal cell carcinoma, offering exceptional cancer control with minimal side effects.
Nephrology October 9th 2023
Don’t miss this crucial update on how biomarker-guided first-line treatment can substantially improve survival rates in advanced NSCLC patients.
Oncology, Medical October 9th 2023
Medical Professionals Reference (MPR)
Takeda’s decision to withdraw Exkivity from the US market raises questions about treatment alternatives for NSCLC patients with specific EGFR mutations; stay updated on this evolving situation.
Discover how local therapy options like radiotherapy and radical prostatectomy can significantly improve overall survival rates in cN1 prostate cancer patients.
OBR Oncology
The increasing acquisition of oncology practices by private equity firms poses new challenges to healthcare ethics and operations. Stay informed and be prepared to advocate for patient-centric reforms.
Hematology/Oncology October 9th 2023
The Epoch Times
Discover the emerging evidence on the cancer risks associated with commonly prescribed medications and what it means for your prescribing habits.
CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH